Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11
|
| pubmed:dateCreated |
1989-6-2
|
| pubmed:abstractText |
The prevalence of Campylobacter pylori in gastric mucosa was investigated prospectively (by histology, cytology, bacterial culture and urease rapid-test) in 302 patients of a routine gastroenterological endoscopy programme. According to the histopathological findings the following prevalence of C. pylori was established: 3 of 35 normals (9%); 116 of 167 with antral gastritis (69%), 28 of 40 with gastric ulcers (70%); 26 of 33 with duodenal ulcers (79%); 5 of 27 with other conditions (19%). The activity degree of the gastritis correlated closely with the presence of C. pylori. In a prospective open trial 110 patients with antral gastritis or gastroduodenal ulcer were treated according to the following schedule: (a) bismuth subsalicylate, 1800 mg/d for four weeks (35 patients); (b) amoxycillin 2250 mg/d for two weeks (6); (c) ranitidine 300 mg/d for four weeks (26); (d) bismuth plus amoxycillin (20); (e) bismuth plus ranitidine (23). Immediately after the end of treatment and four weeks later the elimination rates were: (a) bismuth 51% (18) and 23% (8), respectively; (b) amoxycillin 50% (3) and 17% (1); (c) ranitidine 0% (0); (d) bismuth plus amoxycillin 60% (12) and 25% (5); (e) bismuth plus ranitidine 43% (10) and 17% (4). These data indicate that treatment with bismuth plus amoxycillin will achieve a negative bacterial result in about half the patients. But frequently as early as four weeks later C. pylori can again be demonstrated, so that the long-term elimination rate is only 15-30%.
|
| pubmed:language |
ger
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amoxicillin,
http://linkedlifedata.com/resource/pubmed/chemical/Bismuth,
http://linkedlifedata.com/resource/pubmed/chemical/Organometallic Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Ranitidine,
http://linkedlifedata.com/resource/pubmed/chemical/Salicylates,
http://linkedlifedata.com/resource/pubmed/chemical/bismuth subsalicylate
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
0012-0472
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
17
|
| pubmed:volume |
114
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
407-13
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:2707124-Adult,
pubmed-meshheading:2707124-Aged,
pubmed-meshheading:2707124-Aged, 80 and over,
pubmed-meshheading:2707124-Amoxicillin,
pubmed-meshheading:2707124-Biopsy,
pubmed-meshheading:2707124-Bismuth,
pubmed-meshheading:2707124-Campylobacter,
pubmed-meshheading:2707124-Campylobacter Infections,
pubmed-meshheading:2707124-Drug Evaluation,
pubmed-meshheading:2707124-Drug Therapy, Combination,
pubmed-meshheading:2707124-Duodenum,
pubmed-meshheading:2707124-Female,
pubmed-meshheading:2707124-Gastrointestinal Diseases,
pubmed-meshheading:2707124-Gastroscopy,
pubmed-meshheading:2707124-Germany, West,
pubmed-meshheading:2707124-Humans,
pubmed-meshheading:2707124-Male,
pubmed-meshheading:2707124-Middle Aged,
pubmed-meshheading:2707124-Organometallic Compounds,
pubmed-meshheading:2707124-Prospective Studies,
pubmed-meshheading:2707124-Ranitidine,
pubmed-meshheading:2707124-Salicylates,
pubmed-meshheading:2707124-Stomach
|
| pubmed:year |
1989
|
| pubmed:articleTitle |
[Epidemiology and therapy of Campylobacter pylori infection].
|
| pubmed:affiliation |
Abteilung für Gastroenterologie und Hepatologie im Zentrum Innere Medizin, Medizinische Hochschule Hannover.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
English Abstract,
Controlled Clinical Trial
|